Kadmon Initiates Dosing In Study For Systemic Sclerosis Drug
Zacks Investment Research | Jul 10, 2019 05:51AM ET
Kadmon Holdings, Inc. (NYSE:KDMN) announced that the first patient has been dosed in a phase II study of KD025 to treat diffuse cutaneous systemic sclerosis (SSc).
The phase II KD025-209 study will randomize 60 adults with SSc to receive KD025 200 mg QD, KD025 200 mg BID or placebo (20 per arm) for 24 weeks, followed by an open-label extension period to allow treatment for up to 52 weeks. The primary endpoint is the Combined Response Index for Systemic Sclerosis (CRISS) score at 24 weeks.
Share price of the company has increased 11% year to date compared with the industry ’s growth of 3.4%.
KD025, the company’s advanced product candidate, is an oral small molecule inhibitor of Rho-associated coiledcoil kinase 2 (ROCK2). The company is conducting an open-label registration study of KD025 for the treatment of chronic graft-versus-host disease (cGVHD), a complication arising from allogenic hematopoietic stem cell transplantation.
The company is also conducting a phase II proof-of-concept study of KD025 for the treatment of idiopathic pulmonary fibrosis (IPF). Initial findings from this study demonstrated clinical benefit and tolerability of KD025 in IPF. The company expects data from this study to support the ongoing development of its novel ROCK inhibitors for the treatment of fibrotic diseases, including IPF.
Another company, Corbus Pharmaceuticals Holdings, Inc.’s (NASDAQ:CRBP) lead product, lenabasum, is being developed to treat four life-threatening diseases — systemic sclerosis (SSc), cystic fibrosis (CF), dermatomyositis (DM) and systemic lupus erythematosus (SLE).
Zacks Rank and Other Stocks to Consider
Kadmon currently has a Zacks Rank #1 (Strong Buy).
Some other similar-ranked stocks in the biotech sector are Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Applied Genetics Technologies Corp. (NASDAQ:AGTC) . You can see .
Alnylam’s loss per share estimates have narrowed from $6.90 to $6.43 for 2020 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average beat of 8.93%.
Applied Genetics’ loss per share estimates have narrowed from $2.39 to $2.15 for 2020 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average beat of 83.47%.
Get The News You Want
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.